Metagenomi, Inc.

NASDAQ•MGX

CEO: Dr. Brian Charles Thomas Ph.D.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2006-04-06

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Contact Information

5959 Horton Street, 7th Floor, EmeryVille, CA, 94608, United States

510-871-4880

www.metagenomi.co

Market Cap

$58.95M

P/E (TTM)

-0.7

17.5

Dividend Yield

52W High

$3.95

52W Low

$1.23

52W Range

13%

Rank39Top 39.1%

4.2

F-Score

Modified Piotroski Analysis

Based on 4-year fundamentals

Average • 4.2 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2022-2025

Financial Dashboard

Q4 2025 Data

Revenue

$3.91M+0.00%

4-Quarter Trend

EPS

-$0.60+0.00%

4-Quarter Trend

FCF

-$23.63M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Lead Program Shows Curative Potential MGX-001 Hemophilia A program demonstrated curative Factor VIII activity in NHPs, supporting best-in-class treatment potential.

Strategic Pipeline Reprioritization Complete Late 2025 strategic evolution focused capital on lead programs utilizing advanced genome editing capabilities for higher success probability.

Workforce Cut Extends Cash Runway Workforce reduced by 25% in Q4 2025, successfully extending anticipated cash runway into the fourth quarter of 2027.

Substantial Cash and Securities Position Cash, cash equivalents, and AFS securities totaled $160.8M as of December 31, 2025, funding near-term operations.

Risk Factors

Expect Continued Operating Losses Net loss was $87.9M in 2025; company expects increasing operating losses and requires substantial additional funding for growth.

Very Early Stage Development Hurdles Very early development efforts; company has not yet initiated clinical development for any product candidate, facing many years until potential commercialization.

Novel Technology Competitive Risks Genome editing field evolves rapidly; new technologies may discover significant advantages over current systems, materially harming business prospects.

Intellectual Property Protection Uncertain Commercial success depends on obtaining broad IP protection; patent enforcement is costly, and scope of protection remains uncertain globally.

Outlook

Advance MGX-001 Toward IND Remain on track for regulatory submission, targeting Investigational New Drug application filing in the fourth quarter of 2026 for MGX-001.

Initiate Clinical Trials in 2027 Subject to regulatory clearance, the company plans to initiate clinical trials for lead hemophilia A candidate MGX-001 during 2027.

Progress Secreted Protein Programs Leveraging MGX-001 system, evaluating AT-III deficiency applications and advancing other secreted protein deficiencies toward proof-of-concept.

Continue Ionis Collaboration Efforts Wave 1 targets (APOC3, TTR, AGT) remain in lead optimization phase, focusing on achieving protein reduction via gene knockout.

Peer Comparison

Revenue (TTM)

STRO

$105.65M

-34.4%

ZNTL

$26.87M

-33.8%

MGX

$25.21M

-51.8%

Gross Margin (Latest Quarter)

SRZN

100.0%

+0.0pp

STRO

100.0%

+0.0pp

TCRX

71.8%

-30.5pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
ARMP	$387.01M	-8.2	70.3%	198.5%
IRD	$333.79M	-60.7	-452.3%	0.0%
SRZN	$222.00M	-2.6	-4404.2%	7.5%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

-1.8%

Flat Growth

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:Mar 16, 2026

EPS:-$0.58

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data